215 related articles for article (PubMed ID: 21062490)
21. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
22. Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever.
Saijo M; Georges-Courbot MC; Marianneau P; Romanowski V; Fukushi S; Mizutani T; Georges AJ; Kurata T; Kurane I; Morikawa S
Clin Vaccine Immunol; 2007 Sep; 14(9):1182-9. PubMed ID: 17634509
[TBL] [Abstract][Full Text] [Related]
23. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
[TBL] [Abstract][Full Text] [Related]
24. Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report.
Grove JN; Branco LM; Boisen ML; Muncy IJ; Henderson LA; Schieffellin JS; Robinson JE; Bangura JJ; Fonnie M; Schoepp RJ; Hensley LE; Seisay A; Fair JN; Garry RF
Virol J; 2011 Jun; 8():314. PubMed ID: 21689444
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.
Bausch DG; Rollin PE; Demby AH; Coulibaly M; Kanu J; Conteh AS; Wagoner KD; McMullan LK; Bowen MD; Peters CJ; Ksiazek TG
J Clin Microbiol; 2000 Jul; 38(7):2670-7. PubMed ID: 10878062
[TBL] [Abstract][Full Text] [Related]
26. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
Heinrich ML; Boisen ML; Nelson DKS; Bush DJ; Cross RW; Koval AP; Hoffmann AR; Beddingfield BJ; Hastie KM; Rowland MM; Aimukanova I; Koval S; Lathigra R; Borisevich V; Momoh M; Sandi JD; Goba A; Odia L; Baimba F; Aiyepada JO; Ebo B; Eromon P; Ugwu C; Folarin O; Olumade T; Onyechi MN; Etafo J; Adeyemi R; Ella EE; Aminu M; Gomerep SS; Eke MA; Ogunsanya O; Akpede GO; Asogun DO; Okogbenin SA; Okokhere PO; Holst J; Shaffer JG; Schieffelin JS; Geisbert TW; Saphire EO; Happi CT; Grant DS; Garry RF; Branco LM
Sci Rep; 2020 Sep; 10(1):16030. PubMed ID: 32994446
[TBL] [Abstract][Full Text] [Related]
27. Lassa virus glycoprotein complex review: insights into its unique fusion machinery.
Pennington HN; Lee J
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35088070
[TBL] [Abstract][Full Text] [Related]
28. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance.
Branco LM; Matschiner A; Fair JN; Goba A; Sampey DB; Ferro PJ; Cashman KA; Schoepp RJ; Tesh RB; Bausch DG; Garry RF; Guttieri MC
Virol J; 2008 Jun; 5():74. PubMed ID: 18538016
[TBL] [Abstract][Full Text] [Related]
29. Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments.
Hulseberg CE; Fénéant L; Szymańska KM; White JM
mBio; 2018 Jan; 9(1):. PubMed ID: 29295909
[TBL] [Abstract][Full Text] [Related]
30. Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers.
Gale TV; Horton TM; Grant DS; Garry RF
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005943. PubMed ID: 28922385
[TBL] [Abstract][Full Text] [Related]
31. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges.
Shaffer JG; Schieffelin JS; Gbakie M; Alhasan F; Roberts NB; Goba A; Randazzo J; Momoh M; Moon TD; Kanneh L; Levy DC; Podgorski RM; Hartnett JN; Boisen ML; Branco LM; Samuels R; Grant DS; Garry RF;
PLoS One; 2019; 14(3):e0214284. PubMed ID: 30921383
[TBL] [Abstract][Full Text] [Related]
32. Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.
Borenstein-Katz A; Shulman A; Hamawi H; Leitner O; Diskin R
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728269
[TBL] [Abstract][Full Text] [Related]
33. Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization.
Acciani M; Alston JT; Zhao G; Reynolds H; Ali AM; Xu B; Brindley MA
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679759
[TBL] [Abstract][Full Text] [Related]
34. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
[TBL] [Abstract][Full Text] [Related]
35. Genetic diversity among Lassa virus strains.
Bowen MD; Rollin PE; Ksiazek TG; Hustad HL; Bausch DG; Demby AH; Bajani MD; Peters CJ; Nichol ST
J Virol; 2000 Aug; 74(15):6992-7004. PubMed ID: 10888638
[TBL] [Abstract][Full Text] [Related]
36. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.
Goba A; Khan SH; Fonnie M; Fullah M; Moigboi A; Kovoma A; Sinnah V; Yoko N; Rogers H; Safai S; Momoh M; Koroma V; Kamara FK; Konowu E; Yillah M; French I; Mustapha I; Kanneh F; Foday M; McCarthy H; Kallon T; Kallon M; Naiebu J; Sellu J; Jalloh AA; Gbakie M; Kanneh L; Massaly JL; Kargbo D; Kargbo B; Vandi M; Gbetuwa M; Gevao SM; Sandi JD; Jalloh SC; Grant DS; Blyden SO; Crozier I; Schieffelin JS; McLellan SL; Jacob ST; Boisen ML; Hartnett JN; Cross RW; Branco LM; Andersen KG; Yozwiak NL; Gire SK; Tariyal R; Park DJ; Haislip AM; Bishop CM; Melnik LI; Gallaher WR; Wimley WC; He J; Shaffer JG; Sullivan BM; Grillo S; Oman S; Garry CE; Edwards DR; McCormick SJ; Elliott DH; Rouelle JA; Kannadka CB; Reyna AA; Bradley BT; Yu H; Yenni RE; Hastie KM; Geisbert JB; Kulakosky PC; Wilson RB; Oldstone MB; Pitts KR; Henderson LA; Robinson JE; Geisbert TW; Saphire EO; Happi CT; Asogun DA; Sabeti PC; Garry RF;
J Infect Dis; 2016 Oct; 214(suppl 3):S110-S121. PubMed ID: 27402779
[TBL] [Abstract][Full Text] [Related]
37. A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection.
Bond N; Schieffelin JS; Moses LM; Bennett AJ; Bausch DG
Am J Trop Med Hyg; 2013 Feb; 88(2):241-4. PubMed ID: 23390223
[TBL] [Abstract][Full Text] [Related]
38. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
39. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study.
Grant DS; Engel EJ; Roberts Yerkes N; Kanneh L; Koninga J; Gbakie MA; Alhasan F; Kanneh FB; Kanneh IM; Kamara FK; Momoh M; Yillah MS; Foday M; Okoli A; Zeoli A; Weldon C; Bishop CM; Zheng C; Hartnett J; Chao K; Shore K; Melnik LI; Mucci M; Bond NG; Doyle P; Yenni R; Podgorski R; Ficenec SC; Moses L; Shaffer JG; Garry RF; Schieffelin JS
PLoS Negl Trop Dis; 2023 Feb; 17(2):e0010938. PubMed ID: 36758101
[TBL] [Abstract][Full Text] [Related]
40. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
